Inci Yildiz

Inci Yildiz

Auto-generated profile, based on publicly available information

Inci Yildiz

Ağrı İbrahim Çeçen University, Faculty of Pharmacy, Ağrı, Turkey

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 June 2015 in Pediatric Hematology and Oncology
Verified
Journal Article
Closed access
PDF file
IYInci Yildiz
Inci Yildiz
GOGul Nihal Ozdemir
Gul Nihal Ozdemir
TCTiraje Celkan
Tiraje Celkan
SYSelen Soylu Yaliman
Selen Soylu Yaliman
SKSerap Karaman
Serap Karaman
HAHilmi Apak
Hilmi Apak
Initial Management of Childhood Acute Immune Thrombocytopenia: Single-Center Experience of 32 Years. . ???aop.label???. doi: 10.3109/08880018.2015.1040931

19 May 2002 in Medical and Pediatric Oncology
Verified
Journal Article
Closed access
PDF file
TCTiraje Celkan
Tiraje Celkan
AOAlp Ozkan
Alp Ozkan
HAHilmi Apak
Hilmi Apak
SKSebuh Kuruoglu
Sebuh Kuruoglu
LYLebriz Yuksel
Lebriz Yuksel
IYInci Yildiz
Inci Yildiz

28 April 2025 in Oriental Journal of Chemistry
Verified
Journal Article
Open access
PDF file
IYİsMail Yildiz
İsMail Yildiz
HÇHülya Çelik
Hülya Çelik
Crocus sativus L., known as saffron, is a plant of great medicinal, commercial and historical importance, which has been used for various purposes from ancient times to the present day. Saffron, which is often used to add flavor and color to dishes, is one of the most expensive spices in the world, which is quite difficult to cultivate due to the use of only dried stigma parts. Nowadays, with the increasing number of effective applications of saffron in the medical field and alternative medicine, it is of interest to many researchers. Saffron has many beneficial effects such as supporting digestion, pain relieving properties, calming effects, being good for insomnia, strengthening memory and increasing concentration. In addition, experiments on laboratory animals show that saffron can also be effective on cancer treatment. Therefore, as a result of extensive research on saffron, it is possible to expand the use of saffron in modern medicine. With a better understanding of the potential health benefits of saffron and the promotion of its proper use, the saffron plant could become an important source in the medical field in the future.

1 November 2008 in Pediatric Blood & Cancer
Verified
Journal Article
Open access
PDF file
TCTiraje Celkan
Tiraje Celkan
IYInci Yildiz
Inci Yildiz

6 December 2014 in Blood
Verified
Journal Article
Open access
TCTiraje Celkan
Tiraje Celkan
GOGul Nihal Ozdemir
Gul Nihal Ozdemir
HAHilal Akı
Hilal Akı
HAHilmi Apak
Hilmi Apak
AÖAlp Özkan
Alp Özkan
IYİnci Yıldız
İnci Yıldız
Aim: To investigate the clinical features, diagnostic and treatment results and long-survival of children with HL at a single center in Turkey. Methods: Retrospective data were extracted from medical records of children (<18 years old) diagnosed and treated for HL between 1975 and 2012 at Istanbul University, Cerrahpasa Medical Faculty. Results: Twohundred-fortyeight patients (M/F: 1.8) were identified for analysis. Mean age at diagnosis was 10 years. Four-percent were stage 1, 43% were stage 2, 34% were stage 3 and 17% were stage 4 at diagnosis. B symptoms were present in 105 children (42%). Mixed cellular was the most common subtype (50%) followed by nodular sclerosis. MOPP regimen was primarily used until 1989 along with extended field radiotherapy (30-40 Gy) after 1989 ABVD with involved field RT (20-25 Gy) was the treatment of choice. Onehundred-fortyseven patients (42%) had radiotherapy. Median follow-up time was 14.3 years (range: 5 months-38 years). PET was used for assessment in 45 cases. Ten year overall survival rate was 99%. Ten year event free survival rate (EFS) was 90%. Univariate analysis showed that stage, histological subtype, presence of B symptoms and hematological parameters were not related to OS while treatment regimen correlated. Twenty-six patients relapsed and 17 patients expired on follow-up. Ten patients who relapsed were treated with autologous stem cell transplantation, 3 of them relapsed again and were treated with brentixumab. Secondary tumours developed in 4 patients (1.6%). One had AML, 1 osteosarcoma, 1 thyroid papillary cancer and 1 had craniopharyngioma. Conclusion: Ethnic and regional differences in the epidemiology and pathological aspects of HL may be associated with differences in clinical features and prognosis however we found that clinical features and treatment outcomes are similiar in Turkish patients. Our results showed that hematological parameters and B symptoms were not significant prognostic parameters. Disclosures: No relevant conflicts of interest to declare.

16 November 2005 in Blood
Verified
Journal Article
Open access
TCTiraje Celkan
Tiraje Celkan
SKSerap Karaman
Serap Karaman
AOAlp Ozkan
Alp Ozkan
HAHilmi Apak
Hilmi Apak
ACAylin Canpolat
Aylin Canpolat
IYInci Yildiz
Inci Yildiz
Approximately 25–30 % of children newly diagnosed with acute lymphoblastic leukemia (ALL) will eventually experience leukemic relapse. Bone marrow is the most common site of recurrence. Usually achieving a durable second remission is complicated by toxicity and resistance of the disease. Here we documented our patients in order to see the prognosis of relapsed pediatric ALL cases. RESULTS. From August 1990 to August 2005 children diagnosed with ALL and treated with BFM based protocols in Cerrahpasa Medical Faculty Pediatric Hematology-Oncology Department were enrolled to this study. There were 225 children aged median 6 years( 3 months–18 years) (136 boys/89 girls), 28 % SR, 50 % MR, 22 % HR. The whole group EFS is 72,6 % and RFI 81,8 %. Twenty-nine (12,8 %) patients were relapsed. Bone marrow recurrences were isolated in 19 patients, and combined with an extramedullary site in 8 patients (4 CNS, 2 testis, 1 retinal,1 dermal). Only two patients had isolated extramedullary site (testis) relapse. The median time to recurrence was 23 months (range 4–128 months). Five patients refused a secondary treatment. Of 24 chemotherapy given patients, 6 patients were lost just after induction therapy due to toxicity before a reliable remission evaluation was done. In three early relapses a second remission could not be attained. Twenty-one patients (72.4 %) achieved a second remission (median length, 4 months; range, 1–114 months)( mean16 ± 80 months). The 5-year survival probability among all patients was 27.2 % ± 8.2 %. Of 8 surviving patients, 3 are in remission more than 5 years, 3 are in remission 2–5 years of period and only 2 less than 1 year. One patient who relapsed for second time is in 3th remission for 65 months period. Bone marrow transplantation was the done for only 3 patients, one is very newly done, the other two relapsed after engrafmant and were lost. CONCLUSIONS. Despite acceptable long-term second EFS rates for a minor group of patients, childhood ALL recurrences signal a poor outcome being the problem of childhood ALL therapy.